Moderna's (MRNA) Spixevax Approval Is Already Baked In To The Price - BofA Securities
Tweet Send to a Friend
BofA Securities analyst Geoff Meacham reiterated a Neutral rating and $180.00 price target on Moderna (NASDAQ: MRNA) after gaining more ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
